AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SEATTLE -- Physicians may have become too eager to add metformin reflexively to treatment of adolescent patients with polycystic ovary syndrome, Dr. S. Jean Emans said at the annual meeting of the Society for Adolescent Medicine.
"I don't think we are there yet in terms of good clinical outcome data," said Dr. Emans, chief of adolescent medicine at Children's Hospital, Boston.
Metformin has been shown to decrease levels of luteinizing hormone, androstenedione, and testosterone in patients with polycystic ovary syndrome (PCOS) in a randomized trial. In a study of 15 obese adolescents with PCOS published last year, metformin proved that it could better their glucose tolerance and insulin sensitivity, as well as decrease serum androgens. In trials of diabetic adolescents, metformin has produced some weight loss. However, "the studies are clearly short term. There are long-term risks and benefits that have not been defined," she said.
Regarding the two features of PCOS that tend to most bother adolescents, hirsutism and weight, metformin is not necessarily the first choice for treatment, she said. Metformin's impact on hirsutism is variable. The first alternative for ...
Source: HighBeam Research, Scant outcome data on metformin in PCOS teens; expert...